Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 50,347	$ 55,516
Short-term investments – available for sale	880,093	306,563
Prepaid clinical trial and preclinical study costs	4,476	2,624
Prepaid expenses and other current assets	1,733	2,522
Total current assets	936,649	367,225
Right-of-use assets	1,113	1,126
Deferred financing costs	80	106
Deposits	46	33
Total assets	937,888	368,490
Current liabilities:
Accounts payable	254	7,512
Other accrued liabilities	24,951	11,299
Lease liability, current	480	324
Total current liabilities	25,685	19,135
Lease liability, net of current portion	755	936
Total long-term liabilities	755	936
Total liabilities	26,440	20,071
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023
Common stock, $0.00001 par value: 300,000,000 shares authorized at September 30, 2024 and December 31, 2023; 111,434,821 shares issued and outstanding at September 30, 2024 and 100,113,770 shares issued and outstanding at December 31, 2023	1	1
Treasury stock at cost, no shares at September 30, 2024 and 2,193,251 shares at December 31, 2023	0	(6,795)
Additional paid-in capital	1,362,305	733,546
Accumulated deficit	(452,490)	(377,944)
Accumulated other comprehensive loss	1,632	(389)
Total stockholders’ equity	911,448	348,419
Total liabilities and stockholders’ equity	$ 937,888	$ 368,490